Ppis + Clarithromycin + Amoxicillin Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: (PPI): 30 mg + Amoxicillin: 500 mg + Clarithromycin: 500 mg
Reference Brands: Prevpac(US)
Category:
Gastrointestinal Drugs
PPIs bind to stomach H+/K+ ATPase enzymes, reducing acid secretion, creating a less hospitable environment for H. pylori. Clarithromycin and Amoxicillin target and eliminate the bacteria. The combination effectively eradicates H. pylori, relieves ulcers, and prevents gastric cancer. Benefits include symptom relief, mucosal healing, and reduced recurrence.
PPIs + Clarithromycin + Amoxicillin tablets is available in Tablets
and strengths such as (PPI): 30 mg + Amoxicillin: 500 mg + Clarithromycin: 500 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, PPIs + Clarithromycin + Amoxicillin tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
PPIs + Clarithromycin + Amoxicillin tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
PPIs combined with clarithromycin and amoxicillin tablets are approved in the US by the FDA and in the EU via EMA for Helicobacter pylori eradication. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews clinical trial and quality data for timely approval, while the EMA ensures compliance with regional safety and manufacturing standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence to regional regulations supports swift approval, safe use, and worldwide availability, helping healthcare providers effectively treat H. pylori infections and prevent gastric complications globally.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing